ClinConnect ClinConnect Logo
Search / Trial NCT04814316

Effects of Lansoprazole on Bone Turnover Markers

Launched by ATATURK UNIVERSITY · Mar 23, 2021

Trial Information

Current as of August 25, 2025

Completed

Keywords

Lansoprazole Bone Turnover Gastroesophageal Reflux

ClinConnect Summary

This study is planned to be conducted with children who are diagnosed with gastroesophageal reflux or gastroesophageal reflux disease aged 2-18 years and healthy volunteers. The diagnosis of gastroesophageal reflux will be made in accordance with the guidelines of North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Written and verbal consent will be obtained from patients/healthy volunteers and/or parents who want to participate in the study. Serum calcium, magne...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Patients diagnosed with gastroesophageal reflux or gastroesophageal reflux disease aged 16 to18 years.
  • Exclusion Criteria:
  • Patients with a malabsorptive disease.
  • Patients with any chronic disease.
  • Patients who use any medication that may affect calcium and bone metabolism.
  • Patients who used proton pumps inhibitor within the last 3 months.
  • Patients who do not use lansoprazole in the study group.
  • Patients whose blood and urine samples are not taken in the eighth week of treatment.

About Ataturk University

Atatürk University, located in Erzurum, Turkey, is a prominent academic institution dedicated to advancing research and education across various disciplines. As a clinical trial sponsor, the university leverages its extensive resources and expertise to facilitate innovative medical research aimed at improving patient outcomes and contributing to the global body of health knowledge. Committed to ethical standards and rigorous scientific methodologies, Atatürk University collaborates with healthcare professionals, researchers, and regulatory bodies to ensure the integrity and efficacy of its clinical trials, ultimately enhancing the quality of care and driving advancements in medical science.

Locations

Erzurum, , Turkey

Patients applied

0 patients applied

Trial Officials

Ali Islek, MD

Principal Investigator

Ataturk University School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials